Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.053
V. Dalal, Rincy Reji, R. Jain, Sreelakshmi S Mohandas, Prasad N Bali
COVID-19 is a severe acute respiratory infection affecting worldwide population. There are many cases of complications after the COVID exposure occurring nowadays. One among is Post-COVID-19 Multisystem Inflammatory Syndrome in Children (MIS-C). As per CDC report till March 1, 2021, 2617 cases of MIS-C were meeting the definite case criteria and among 33 death cases were reported. Here we report a case of COVID-19 associated Multi-system inflammatory syndrome in a child (MIS-C) interpreted with WHO case definition criteria. The patient was a 7-year-old boy, with initial presentation of moderate fever, non-itchy red blanching rashes, breathlessness, later progressed to cardiogenic shock accompanied by positive SARS-CoV-2 antigen result. The emergency cardiogenic shock treatment protocol was followed with initial stabilization and resuscitation strategy. He was successfully managed by three days of IV Immunoglobulin 2g/kgand Methylprednisolone 2mg/kg/day therapy along with other supportive treatments. The patient was discharged after 20 days of hospital stay with improved health condition. Our case report will strengthen the exposure-outcome relations between the coronavirus infection and MIS-C, moreover the strategies carried out in our case will be a future direction for the effective management of MIS-C.
{"title":"Post- COVID-19 multisystem inflammatory syndrome in children","authors":"V. Dalal, Rincy Reji, R. Jain, Sreelakshmi S Mohandas, Prasad N Bali","doi":"10.18231/j.ijirm.2021.053","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.053","url":null,"abstract":"COVID-19 is a severe acute respiratory infection affecting worldwide population. There are many cases of complications after the COVID exposure occurring nowadays. One among is Post-COVID-19 Multisystem Inflammatory Syndrome in Children (MIS-C). As per CDC report till March 1, 2021, 2617 cases of MIS-C were meeting the definite case criteria and among 33 death cases were reported. Here we report a case of COVID-19 associated Multi-system inflammatory syndrome in a child (MIS-C) interpreted with WHO case definition criteria. The patient was a 7-year-old boy, with initial presentation of moderate fever, non-itchy red blanching rashes, breathlessness, later progressed to cardiogenic shock accompanied by positive SARS-CoV-2 antigen result. The emergency cardiogenic shock treatment protocol was followed with initial stabilization and resuscitation strategy. He was successfully managed by three days of IV Immunoglobulin 2g/kgand Methylprednisolone 2mg/kg/day therapy along with other supportive treatments. The patient was discharged after 20 days of hospital stay with improved health condition. Our case report will strengthen the exposure-outcome relations between the coronavirus infection and MIS-C, moreover the strategies carried out in our case will be a future direction for the effective management of MIS-C.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77228671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.048
Srihita Mahavadi, Deepika Gujjarlapudi, Veeraiah Namburu, N. Hassan, N. Duvvur
SARS-CoV-2 (previously called 2019-nCoV), and was named in February 2020 as COVID-19 by the WHO. Estimate the seroprevalence of antibodies against SARS-CoV-2 in health care workers (HCW) and general population in the first and second wave and assess the pattern of antibody response in HCW with COVID-19 infected and non-infected over pre and post-vaccination. This was a cohort observational retrospective study done to analyse the seroprevalence in HCW from July-September 2020, in the general population in the first wave (December 2020–February 2021) and second wave (March–September 2021). SARS-CoV-2 testing by RT-PCR (QIAGEN Company). Testing for quantitative IgG and IgM (Abbott) antibodies, Total Antibodies (Roche), Anti-SARS-CoV-2 IgG RBD(Roche), and Anti-SARS-CoV-2 IgG S1/S2 (Diasorin XL), to assess the pattern of antibody responses categorized as baseline (before the first dose), 14 days after 1st dose, before 2nd dose (45 days post first dose), 14 days post-second dose. Among 1340 HCW, 1268 underwent RT-PCR testing, 540 serology testing and 431 underwent both testing. We identified 164 of 1268 positive RT-PCR and using serology testing 229 of 540 were seropositive. High seropositivity was observed in age group 26-45 years (44.9%) HCW, in males (65.9%), nurses (47.3%), and ward staff (48.6%). High seroprevalence in general population-76.07% in the 2nd wave compared to 1st wave (44.67%). SARS-CoV-2 antibodies showed gender associated seroprevalence and higher immune response was observed in COVID-19 infected than in non-infected HCW pre- and post-vaccination.
{"title":"Evaluation of antibodies against SARS-CoV-2 and their patterns of response in health care workers and general population at a tertiary care Centre","authors":"Srihita Mahavadi, Deepika Gujjarlapudi, Veeraiah Namburu, N. Hassan, N. Duvvur","doi":"10.18231/j.ijirm.2021.048","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.048","url":null,"abstract":"SARS-CoV-2 (previously called 2019-nCoV), and was named in February 2020 as COVID-19 by the WHO. Estimate the seroprevalence of antibodies against SARS-CoV-2 in health care workers (HCW) and general population in the first and second wave and assess the pattern of antibody response in HCW with COVID-19 infected and non-infected over pre and post-vaccination. This was a cohort observational retrospective study done to analyse the seroprevalence in HCW from July-September 2020, in the general population in the first wave (December 2020–February 2021) and second wave (March–September 2021). SARS-CoV-2 testing by RT-PCR (QIAGEN Company). Testing for quantitative IgG and IgM (Abbott) antibodies, Total Antibodies (Roche), Anti-SARS-CoV-2 IgG RBD(Roche), and Anti-SARS-CoV-2 IgG S1/S2 (Diasorin XL), to assess the pattern of antibody responses categorized as baseline (before the first dose), 14 days after 1st dose, before 2nd dose (45 days post first dose), 14 days post-second dose. Among 1340 HCW, 1268 underwent RT-PCR testing, 540 serology testing and 431 underwent both testing. We identified 164 of 1268 positive RT-PCR and using serology testing 229 of 540 were seropositive. High seropositivity was observed in age group 26-45 years (44.9%) HCW, in males (65.9%), nurses (47.3%), and ward staff (48.6%). High seroprevalence in general population-76.07% in the 2nd wave compared to 1st wave (44.67%). SARS-CoV-2 antibodies showed gender associated seroprevalence and higher immune response was observed in COVID-19 infected than in non-infected HCW pre- and post-vaccination.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86503453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.049
Keski Hakan, Demirtunç Refik
We aimed to investigate the effects of Sildenafil on pulmonary artery systolic pressure (PASP) as well as forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) and serum brain-type natriuretic peptide (BNP) levels in stable chronic obstructive pulmonary disease (COPD) patients with erectile dysfunction (ED). This was a prospective non-controlled interventional study that recruited COPD patients with ED between the ages of 49 and 79. International Index of Erectile Dysfunction Form (IIEF-5) was used for the evaluation of ED. Patients who had pulmonary artery systolic pressure >50 mmHg were included in the study. Single-dose Sildenafil 100 mg was administered orally to the patients. Before and after the drug ingestion, spirometry and echocardiographic measurements were performed, and serum BNP levels were measured as well. Forty-five male COPD patients with ED were included. Both percent predicted, and absolute FEV1 values increased significantly after the Sildenafil administration compared with baseline values (p<0.01). Similarly, the FEV1/FVC ratio also increased significantly with the Sildenafil administration compared to baseline values (p<0.01). Pulmonary artery systolic pressure significantly decreased from its baseline value with Sildenafil administration (p<0.01). Serum BNP values significantly reduced with Sildenafil administration compared to the pre-treatment values (p<0.01). This is the first study conducted in COPD patients with erectile dysfunction who had also pulmonary hypertension. The single-dose Sildenafil administration reduced PASP and serum BNP levels significantly. For the first time in the literature, we showed that the spirometric pulmonary function tests, namely FEV1 and FEV1/FVC ratio, improved significantly with the Sildenafil administration.
{"title":"Effects of Sildenafil on spirometric pulmonary function parameters, pulmonary artery systolic pressure and BNP levels in patients with chronic obstructive pulmonary disease and erectile dysfunction","authors":"Keski Hakan, Demirtunç Refik","doi":"10.18231/j.ijirm.2021.049","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.049","url":null,"abstract":"We aimed to investigate the effects of Sildenafil on pulmonary artery systolic pressure (PASP) as well as forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) and serum brain-type natriuretic peptide (BNP) levels in stable chronic obstructive pulmonary disease (COPD) patients with erectile dysfunction (ED). This was a prospective non-controlled interventional study that recruited COPD patients with ED between the ages of 49 and 79. International Index of Erectile Dysfunction Form (IIEF-5) was used for the evaluation of ED. Patients who had pulmonary artery systolic pressure >50 mmHg were included in the study. Single-dose Sildenafil 100 mg was administered orally to the patients. Before and after the drug ingestion, spirometry and echocardiographic measurements were performed, and serum BNP levels were measured as well. Forty-five male COPD patients with ED were included. Both percent predicted, and absolute FEV1 values increased significantly after the Sildenafil administration compared with baseline values (p<0.01). Similarly, the FEV1/FVC ratio also increased significantly with the Sildenafil administration compared to baseline values (p<0.01). Pulmonary artery systolic pressure significantly decreased from its baseline value with Sildenafil administration (p<0.01). Serum BNP values significantly reduced with Sildenafil administration compared to the pre-treatment values (p<0.01). This is the first study conducted in COPD patients with erectile dysfunction who had also pulmonary hypertension. The single-dose Sildenafil administration reduced PASP and serum BNP levels significantly. For the first time in the literature, we showed that the spirometric pulmonary function tests, namely FEV1 and FEV1/FVC ratio, improved significantly with the Sildenafil administration.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"77 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82371600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.046
S. Yadav
{"title":"Booster dose against COVID-19- An important tool in the fight against the SARS-CoV-2","authors":"S. Yadav","doi":"10.18231/j.ijirm.2021.046","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.046","url":null,"abstract":"","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73050714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.055
S. Raina, Sayan Malakar, B. D. Negi, K. Dutt, K. Bharath
We report a case of acute pulmonary embolism (PE) following short term exposure to smoke in an enclosed area. The patient was obese and had type 2 diabetes mellitus. He developed PE as a consequence of acute systemic inflammatory response to short term exposure to smoke and an underlying chronic inflammatory milieu.
{"title":"Acute pulmonary embolism after short term exposure to smoke in an enclosed area","authors":"S. Raina, Sayan Malakar, B. D. Negi, K. Dutt, K. Bharath","doi":"10.18231/j.ijirm.2021.055","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.055","url":null,"abstract":"We report a case of acute pulmonary embolism (PE) following short term exposure to smoke in an enclosed area. The patient was obese and had type 2 diabetes mellitus. He developed PE as a consequence of acute systemic inflammatory response to short term exposure to smoke and an underlying chronic inflammatory milieu.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76184608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.052
Subhajit Sen, Suresh Ramasubban, M. Kumar, Sanjay Bhaumik, Debasis Rout
A 73 years old male, known hypertensive on medication, with the history of SARS-CoV-2 infection nine months ago, presented to us with mucormycosis, he was treated with Liposomal amphotericin B initially. He developed acute kidney injury with recurrent pulmonary oedema requiring ICU admission and Haemodialysis. He later developed catheter related blood stream infection that grew Carbapenem resistant Klebsiella pneumonia and was started on Polymyxin B. However from day 3 of antibiotics he started to develop recurrent respiratory arrest with no apparent cause. He required a brief period of mechanical ventilation and was successfully weaned. He had recurrent such episodes with no apparent cause. After extensive work up and literature search it was diagnosed as Polymyxin B induced respiratory failure. Polymyxins were stopped, patient was discharged in a stable condition after five days of further observation and is currently on follow up with no such episode of dyspnoea.
{"title":"Polymyxin B infusion related respiratory arrest: A case report","authors":"Subhajit Sen, Suresh Ramasubban, M. Kumar, Sanjay Bhaumik, Debasis Rout","doi":"10.18231/j.ijirm.2021.052","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.052","url":null,"abstract":"A 73 years old male, known hypertensive on medication, with the history of SARS-CoV-2 infection nine months ago, presented to us with mucormycosis, he was treated with Liposomal amphotericin B initially. He developed acute kidney injury with recurrent pulmonary oedema requiring ICU admission and Haemodialysis. He later developed catheter related blood stream infection that grew Carbapenem resistant Klebsiella pneumonia and was started on Polymyxin B. However from day 3 of antibiotics he started to develop recurrent respiratory arrest with no apparent cause. He required a brief period of mechanical ventilation and was successfully weaned. He had recurrent such episodes with no apparent cause. After extensive work up and literature search it was diagnosed as Polymyxin B induced respiratory failure. Polymyxins were stopped, patient was discharged in a stable condition after five days of further observation and is currently on follow up with no such episode of dyspnoea.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79746891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.056
Dharm Prakash Dwivedi, Muniza Bai, Abhishek Chauhan, V. Babu, Sneha Leo, Shahana M P
X-ray flips and wrong labelling has been uncomfortably common, and often results in wrong side intervention. Wrong side surgery is indeed the most dramatic and visible form of human errors. Until the 1999 Institute of Medicine report ‘To Err is Human’, the medical fraternity was largely unaware of such preventable medical errors and near misses. We herein, describe a case where X-ray flip and mislabelling led to wrong side intervention in a COVID-19 ICU. Active errors in human performance are inevitable while practising medicine in the current COVID-19 pandemic where difficulties in performing comprehensive systemic examination with the protective gear on, long working hours, work stress, emotions, and fatigue interplay with the errors in technology and increase the chances of errors. We propose the use of point of care ultrasound (POCUS) in COVID-19 ICU’s to aid in the diagnosis and management.
{"title":"Pocus as a tool to avoid diagnostic errors in covid-19 era","authors":"Dharm Prakash Dwivedi, Muniza Bai, Abhishek Chauhan, V. Babu, Sneha Leo, Shahana M P","doi":"10.18231/j.ijirm.2021.056","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.056","url":null,"abstract":"X-ray flips and wrong labelling has been uncomfortably common, and often results in wrong side intervention. Wrong side surgery is indeed the most dramatic and visible form of human errors. Until the 1999 Institute of Medicine report ‘To Err is Human’, the medical fraternity was largely unaware of such preventable medical errors and near misses. We herein, describe a case where X-ray flip and mislabelling led to wrong side intervention in a COVID-19 ICU. Active errors in human performance are inevitable while practising medicine in the current COVID-19 pandemic where difficulties in performing comprehensive systemic examination with the protective gear on, long working hours, work stress, emotions, and fatigue interplay with the errors in technology and increase the chances of errors. We propose the use of point of care ultrasound (POCUS) in COVID-19 ICU’s to aid in the diagnosis and management.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81052338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.045
S. Yadav
{"title":"Omicron variant of SARS-CoV-2- A virus of concern","authors":"S. Yadav","doi":"10.18231/j.ijirm.2021.045","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.045","url":null,"abstract":"","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"178 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88032390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.054
Arjun A S, Prasanna Kumar T, Manjunath H K
Burkholderia Cepacia is a gram negative organism, an uncommon cause of pneumonia. When isolated, it usually represents colonisation. In the presence of immunocompromising conditions, it can cause disease, ranging from mild illness to the highly fatal Cepacia syndrome. The organism is intrinsically resistant to many antibiotics. We report a 57 years old male farmer, who has diabetes mellitus and bronchial asthma, who presented with a acute history of high grade fever, pain abdomen and cough. He was diagnosed with a ruptured liver abscess, with the infection spreading to the right lower lobe. Laparotomy was performed. Pus culture grew Pseudomonas aeruginosa. He improved upon antibiotic therapy, only to return after one month with severe cough, chest X-ray revealing a lung abscess in the right lower lobe. Bronchoalveolar lavage culture grew Burkholderia cepacia, and sensitive antibiotics were initiated, however the patient succumbed to the illness. The implicated source of the organism was the nebulisation solution which he was using regularly. Emphasis should be laid on the need for improved aseptic practices while using medical solutions at either hospital or home setting. An index of suspicion may guide optimal antibiotic prescription practices in susceptible individuals.
{"title":"Burkholderia cepacia: An unusual cause of pneumonia","authors":"Arjun A S, Prasanna Kumar T, Manjunath H K","doi":"10.18231/j.ijirm.2021.054","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.054","url":null,"abstract":"Burkholderia Cepacia is a gram negative organism, an uncommon cause of pneumonia. When isolated, it usually represents colonisation. In the presence of immunocompromising conditions, it can cause disease, ranging from mild illness to the highly fatal Cepacia syndrome. The organism is intrinsically resistant to many antibiotics. We report a 57 years old male farmer, who has diabetes mellitus and bronchial asthma, who presented with a acute history of high grade fever, pain abdomen and cough. He was diagnosed with a ruptured liver abscess, with the infection spreading to the right lower lobe. Laparotomy was performed. Pus culture grew Pseudomonas aeruginosa. He improved upon antibiotic therapy, only to return after one month with severe cough, chest X-ray revealing a lung abscess in the right lower lobe. Bronchoalveolar lavage culture grew Burkholderia cepacia, and sensitive antibiotics were initiated, however the patient succumbed to the illness. The implicated source of the organism was the nebulisation solution which he was using regularly. Emphasis should be laid on the need for improved aseptic practices while using medical solutions at either hospital or home setting. An index of suspicion may guide optimal antibiotic prescription practices in susceptible individuals.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"92 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88087517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Inhalation therapy plays a major role in treatment of respiratory diseases. Correct inhalation technique is crucial for effective clinical outcomes. The aim of this study was to evaluate and analyse technique of use of Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) in patients with respiratory disease. This observational study was conducted at pulmonary outpatient department of a tertiary care hospital. 30 patients were enrolled using convenience sampling. Participants’ demographic and disease specific data was recorded. Participants were asked to use their inhaler just as they would at home. The technique of device use was observed and recorded using inhaler specific checklists. Data collected was analyzed using descriptive statistics. Out of 30 patients 26 were using MDI, 23 of which (92%) performed at least 1 error. Among 4 patients using DPI, 3 (75%) performed at least 1 error. Patients using MDI for more than 1 year performed less errors compared to those who had been using MDI for less than 1 year, however the difference observed was not significant (n=26, p= 0.304). 29 patients (96%) received education about inhaler device use. The most common incorrectly performed steps were “complete exhalation” and “breath hold.” 92% of MDI and 75% of DPI users made at least one error during the inhalation maneuver despite majority being educated about inhaler technique. The most frequently performed incorrect steps for MDI and DPI were “Complete exhalation” and “Breath hold”.
{"title":"Evaluating the technique of using MDI and DPI in patients with respiratory disease","authors":"Rayas Rucha V, Jagtap Tanmay P, Shyam Ashok K, Sancheti Parag K","doi":"10.18231/j.ijirm.2021.047","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.047","url":null,"abstract":"Inhalation therapy plays a major role in treatment of respiratory diseases. Correct inhalation technique is crucial for effective clinical outcomes. The aim of this study was to evaluate and analyse technique of use of Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) in patients with respiratory disease. This observational study was conducted at pulmonary outpatient department of a tertiary care hospital. 30 patients were enrolled using convenience sampling. Participants’ demographic and disease specific data was recorded. Participants were asked to use their inhaler just as they would at home. The technique of device use was observed and recorded using inhaler specific checklists. Data collected was analyzed using descriptive statistics. Out of 30 patients 26 were using MDI, 23 of which (92%) performed at least 1 error. Among 4 patients using DPI, 3 (75%) performed at least 1 error. Patients using MDI for more than 1 year performed less errors compared to those who had been using MDI for less than 1 year, however the difference observed was not significant (n=26, p= 0.304). 29 patients (96%) received education about inhaler device use. The most common incorrectly performed steps were “complete exhalation” and “breath hold.” 92% of MDI and 75% of DPI users made at least one error during the inhalation maneuver despite majority being educated about inhaler technique. The most frequently performed incorrect steps for MDI and DPI were “Complete exhalation” and “Breath hold”.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82118435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：